AvandiaThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

1924 records returned

Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinedionesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: TZDs exhibit significant beneficial effects on aorto-carotid atherosclerosis when assessed using prospectively validated non-invasive techniques. Inferring clinical benefit in the absence of confirmatory outcome trials is questionable and caution should be exercised when interpreting intervention data with surrogate endpoints. TZD-induced congestive cardiac failure or other unknown PPAR-[gamma] adverse effects are plausible explanations for the conflicting results of intervention trials using markers of atherosclerosis and clinical event outcomes. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - November 18, 2009 Category: Endocrinology Authors: D. R. Webb, M. J. Davies, L. J. Gray, K. R. Abrams, B. Srinivasan, S. Das, N. Taub, I. Lawrence, S. Sutton, K. Khunti Source Type: journals

Rosiglitazone does not improve endothelial function in patients with essential hypertensionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Rosiglitazone improves insulin sensitivity in patients with essential hypertension. However, despite this there was no change in endothelial function. Content Type Journal ArticleCategory Oral PresentationsDOI 10.1007/BF03170270Authors S. T. B. Au, Royal Victoria Hospital Regional Centre of Endocrinology and Diabetes Belfast Northern IrelandC. Ennis, Royal Victoria Hospital Regional Endocrine Laboratory Belfast Northern IrelandA. B. Atkinson, Royal Victoria Hospital Regional Centre of Endocrinology and Diabetes Belfast Northern IrelandD. R. McCance, Royal Victoria Hospital Regional Centre of End...
Source: Irish Journal of Medical Science - November 17, 2009 Category: Journals (General) Tags: Irish Journal of Medical Science Source Type: journals

Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over timeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Liraglutide treatment combined with OADs led to rapid improvements in FPG and SBP. Early reductions in HbA1c and body weight were also observed. Adding liraglutide to OADs early on may therefore be a good treatment option for patients with type 2 diabetes. (Source: International Journal of Clinical Practice)
Source: International Journal of Clinical Practice - November 17, 2009 Category: Internal Medicine Authors: B. Gallwitz, A. Vaag, A. Falahati, S. Madsbad Source Type: journals

Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end productsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions and implications: The PPAR[gamma] agonist rosiglitazone increased EPC function and attenuated EPC dysfunction induced by AGEs via upregulating the Akt-eNOS signal pathways of EPCs. (Source: British Journal of Pharmacology)
Source: British Journal of Pharmacology - November 16, 2009 Category: Drugs & Pharmacology Authors: Chun Liang, Yusheng Ren, Hongbin Tan, Zhiqing He, Qijun Jiang, Jianxiang Wu, Yi Zhen, Min Fan, Zonggui Wu Source Type: journals

PPARgamma ligands inhibit telomerase activity and hTERT expression through modulation of the Myc/Mad/Max network, in colon cancer cells.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we demonstrated that 15d-PG J2 and rosiglitazone (an endogenous and synthetic PPARgamma ligand, respectively) inhibited hTERT expression and telomerase activity in CaCo-2 colon cancer cells. Moreover, both ligands inhibited c-Myc protein expression and its E-box DNA binding activity. Additionally, Mad1 protein expression and its E-box DNA binding activity were strongly increased by 15d-PG J2 and, to a lesser extent, by rosiglitazone. Sp1 transcription factor expression and its GC-box DNA binding activity were not affected by both PPARgamma ligands. Results obtained by transient transfection of CaCo-2 cells w...
Source: J Cell Mol Med - November 13, 2009 Category: Molecular Biology Authors: Toaldo C, Pizzimenti S, Cerbone A, Pettazzoni P, Menegatti E, Daniela B, Minelli R, Giglioni B, Dianzani MU, Ferretti C, Barrera G Tags: J Cell Mol Med Source Type: journals

Pioglitazone vs Rosiglitazone in Older Patients With Type 2 DiabetesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Are there differences in cardiac risk with the thiazolidinediones pioglitazone and rosiglitazone? Journal Watch (Source: Medscape Nurses Headlines)
Source: Medscape Nurses Headlines - November 12, 2009 Category: Nursing Tags: Internal Medicine Source Type: info

Repression of NHE1 Expression by PPAR{gamma} Activation Is a Potential New Approach for Specific Inhibition of the Growth of Tumor Cells In vitro and In vivoEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report the identification of a peroxisome proliferator response element in the promoter region of the Na+/H+ transporter gene NHE1, the overexpression of which has been associated with carcinogenesis. Exposure of breast cancer cells expressing high levels of PPAR to its natural and synthetic agonists resulted in downregulation of NHE1 transcription as well as protein expression. Furthermore, the inhibitory effect of activated PPAR on tumor colony-forming ability was abrogated on overexpression of NHE1, whereas small interfering RNA–mediated gene silencing of NHE1 significantly increased the sensitivity of cancer c...
Source: Cancer Research - November 12, 2009 Category: Cancer & Oncology Authors: Kumar, A. P., Quake, A. L., Chang, M. K. X., Zhou, T., Lim, K. S. Y., Singh, R., Hewitt, R. E., Salto-Tellez, M., Pervaiz, S., Clement, M.-V. Tags: Experimental Therapeutics, Molecular Targets, and Chemical Biology Source Type: journals

Thiazolidinediones Reduce Pathological Neovascularization in Ischemic Retina Via an Adiponectin-Dependent Mechanism.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: These data show that TZDs attenuate pathological retinal microvessel formation through APN-mediated modulation of TNF-alpha production. PMID: 19910632 [PubMed - as supplied by publisher] (Source: Arteriosclerosis, Thrombosis and Vascular Biology)
Source: Arteriosclerosis, Thrombosis and Vascular Biology - November 12, 2009 Category: Cardiology Authors: Higuchi A, Ohashi K, Shibata R, Sono-Romanelli S, Walsh K, Ouchi N Tags: Arterioscler Thromb Vasc Biol Source Type: journals

Stretch Reduces Nephrin Expression via an Angiotensin II-AT1-dependent Mechanism in Human Podocytes: Effect of Rosiglitazone.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Increased glomerular permeability to proteins is a characteristic feature of diabetic nephropathy (DN). The slit diaphragm is the major restriction site to protein filtration and the loss of nephrin, a key component of the slit diaphragm, has been demonstrated in both human and experimental DN. Both systemic and glomerular hypertension are believed to be important in the pathogenesis of DN. Human immortalized podocytes were subjected to repeated stretch/relaxation cycles by mechanical deformation using a Stress Unit (10% elongation, 60 cycles/min) in the presence or in the absence of candesartan (1muM), PD123319 (1muM)...
Source: Am J Physiol Renal P... - November 11, 2009 Category: Urology & Nephrology Authors: Miceli I, Burt D, Tarabra E, Camussi G, Cavallo Perin P, Gruden G Tags: Am J Physiol Renal Physiol Source Type: journals

Peroxisome proliferator-activated receptor-γ activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factorEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study investigated the effects of the PPAR-γ agonist, rosiglitazone, on myocardial expression of RAGE and CTGF, extent of cardiac fibrosis, and left ventricular (LV) diastolic function in type 2 diabetic (T2D) rats. Twenty-week-old T2D rats were randomized to treatment with either 20 weeks of rosiglitazone (20 mg/kg) or saline (n = 10 in each group). Serial echocardiographic examinations were performed just before randomization (20 weeks) and at study completion (40 weeks). Fibrosis extent and RAGE and CTGF expression were assessed in previously imaged hearts by picrosirius red stain...
Source: Basic Research in Cardiology - November 10, 2009 Category: Cardiology Tags: Basic Research in Cardiology Source Type: journals

Effects of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics of RosiglitazoneEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Laropiprant (LRPT), a prostaglandin D2 receptor-1 antagonist shown to reduce niacin-induced flushing symptoms, has been combined with niacin for treatment of dyslipidemia. This open-label, randomized, 2-period crossover study assessed the pharmacokinetics of single-dose rosiglitazone in the presence and absence of multiple-dose LRPT. Twelve healthy male and female subjects, 34[ndash]64 years of age, received two, once-daily oral treatments in random sequence separated by [ge]3-day washout: (1) multiple-dose LRPT 40 mg/day for 7 days (Days 1 to 7) coadministered with single-dose rosiglitazone 4 mg on Day 6; (2) single-dose ...
Source: Cardiovascular Therapeutics - November 9, 2009 Category: Cardiology Authors: Jules I. Schwartz, Mark Stroh, Bing Gao, Fang Liu, Kimberly Rosko, Stefan Zajic, Alan J. Meehan, Jon Ruckle, Eseng Lai, John A. Wagner Tags: RESEARCH Source Type: journals

Selective effects of PPARγ agonists and antagonists on human pre-adipocyte differentiationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Both the GW9662 treatment and interfering RNA against PPAR[gamma]2 are able to abrogate RTZ-induced differentiation without a significant change of PPAR[gamma]1 gene expression. These results are consistent with previous results obtained in animal models and suggest that in humans PPAR[gamma]2 may also be the key isoform involved in fat storage. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - November 6, 2009 Category: Endocrinology Authors: C. Leyvraz, M. Suter, C. Verdumo, J.-M. Calmes, A. Paroz, C. Darimont, R. C. Gaillard, F. P. Pralong, V. Giusti Source Type: journals

Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: a meta-analysis of randomized controlled trialsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: DARE Area: Evidence > Disease Focused Reviews CRD Summary: This review found that thiazolidinedione therapy for six months following coronary stenting significantly reduced in-stent restenosis in both diabetic and non-diabetic patients. The review was generally well conducted and the conclusions are likely to be reliable but should be interpreted with some caution due to the possibility of publication bias. [Thiazolidinediones evaluated were pioglitazone (30 mg/day) and rosiglitazone (4mg/day).] CRD Commentary: The review addressed a focused question supported by clearly defined inclusion criteria. The literat...
Source: NeLM - Surgery - November 6, 2009 Category: Surgery Source Type: organizations

Anti-allergic function and regulatory mechanisms of KR62980 in allergen-induced airway inflammation.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, a novel PPARgamma ligand, KR62980, suppresses in vitro Th2 cell differentiation and attenuates in vivo OVA-induced airway inflammation, suggesting a beneficial role for KR62980 in the treatment of allergic asthma and allergic rhinitis. PMID: 19896472 [PubMed - as supplied by publisher] (Source: Biochemical Pharmacology)
Source: Biochemical Pharmacology - November 4, 2009 Category: Drugs & Pharmacology Authors: Won HY, Min HJ, Ahn JH, Yoo SE, Bae MA, Hong JH, Hwang ES Tags: Biochem Pharmacol Source Type: journals

Peroxisome Proliferator-Activated Receptor-{alpha} Control of Lipid and Glucose Metabolism in Human White Adipocytes.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This work aimed at characterizing the role of peroxisome proliferator-activated receptors (PPAR)alpha in human white adipocyte metabolism and at comparing PPARalpha and PPARgamma actions in these cells. Primary cultures of human fat cells were treated with the PPARalpha agonist GW7647 or the PPARgamma agonist rosiglitazone. Changes in gene expression were determined using DNA microrrays and quantitative RT-PCR. Western blot and metabolic studies were performed to identify the biological effects elicited by PPAR agonist treatments. GW7647 induced an up-regulation of beta-oxidation gene expression and increased palmitate...
Source: Endocrinology - November 3, 2009 Category: Endocrinology Authors: Ribet C, Montastier E, Valle C, Bezaire V, Mazzucotelli A, Mairal A, Viguerie N, Langin D Tags: Endocrinology Source Type: journals

Activation of peroxisome proliferator activated receptor gamma in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Systemic administration of thiazolidinediones reduces peripheral inflammation in vivo, presumably by acting at peroxisome proliferator-activated receptor gamma (PPARgamma) in peripheral tissues. Based on a rapidly growing body of literature indicating the CNS as a functional target of PPARgamma actions, we postulated that brain PPARgamma modulates peripheral edema and the processing of inflammatory pain signals in the dorsal horn of the spinal cord. To test this in the plantar carrageenan model of inflammatory pain, we measured paw edema, heat hyperalgesia, and dorsal horn expression of the immediate-early gene c-fos a...
Source: Neuropharmacology - November 2, 2009 Category: Drugs & Pharmacology Authors: Morgenweck J, Abdel-Aleem OS, McNamara KC, Donahue RR, Badr MZ, Taylor BK Tags: Neuropharmacology Source Type: journals

Increased CV risk with rosiglitazone but not pioglitazoneEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 31, 2009 Category: Drugs & Pharmacology Tags: Research article Source Type: journals

Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Commonly measured bone biomarkers suggest that changes in bone resorption may be partly responsible for the increased risk of fracture in women taking thiazolidinediones. PMID: 19875477 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - October 29, 2009 Category: Endocrinology Authors: Zinman B, Haffner SM, Herman WH, Holman RR, Lachin JM, Kravitz BG, Paul G, Jones NP, Aftring RP, Viberti G, Kahn SE, Tags: J Clin Endocrinol Metab Source Type: journals

Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Saxagliptin added to TZD provided statistically significant improvements in key parameters of glycemic control vs. TZD monotherapy and was generally well tolerated. PMID: 19864452 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - October 28, 2009 Category: Endocrinology Authors: Hollander P, Li J, Allen E, Chen R, Tags: J Clin Endocrinol Metab Source Type: journals

Inhibitory effect of evodiamine alone and in combination with rosiglitazone on in vitro adipocyte differentiation and in vivo obesity related to diabetesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
& J-H Cha (Source: International Journal of Obesity)
Source: International Journal of Obesity - October 27, 2009 Category: Eating Disorders and Weight Management Authors: E J BakH G ParkJ M KimJ M KimY-J YooJ-H Cha Source Type: journals

Look at Absolute Event Rates When Interpreting Trial ResultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The low event rate in the RECORD trial of rosiglitazone has led some to question the validity of the results. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2009 Category: Consumer Health News Tags: Cardiology Source Type: news

Peroxisome proliferator-activated receptor-{gamma} ligands induce heme oxygenase-1 in lung fibroblasts by a PPAR{gamma}-independent, glutathione-dependent mechanismEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report here that the PPAR ligands 15d-PGJ2 and 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), which have potent antifibrotic effects in vitro, also strongly induce HO-1 expression in primary human lung fibroblasts. Pharmacological and genetic approaches are used to demonstrate that induction of HO-1 is PPAR independent. Upregulation of HO-1 coincides with decreased intracellular glutathione (GSH) levels and can be inhibited by N-acetyl cysteine (NAC), a thiol antioxidant and GSH precursor. Upregulation of HO-1 is not inhibited by Trolox, a non-thiol antioxidant, and does not involve the transcription factors AP-1 ...
Source: AJP: Lung Cellular and Molecular Physiology - October 26, 2009 Category: Respiratory Medicine Authors: Ferguson, H. E., Thatcher, T. H., Olsen, K. C., Garcia-Bates, T. M., Baglole, C. J., Kottmann, R. M., Strong, E. R., Phipps, R. P., Sime, P. J. Tags: ARTICLES Source Type: journals

Current Understanding of the Role of PPARγ in Gastrointestinal CancersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Numerous studies have indicated that PPARγ plays multiple roles such as in inflammation, cell cycle control, cell proliferation, apoptosis, and carcinogenesis, thus PPARγ contributes to the homeostasis. Many in vitro studies have showed that ligand-induced activation of PPARγ possess antitumor effect in many cancers including CRC. However, the role of PPARγ in gastrointestinal cancers, especially in colorectal cancer, is rather controversial. Nevertheless, some recent studies with the positive results on the possible application of PPARγ ligands, such as Bezafibrate or Rosiglitazone in ga...
Source: PPAR Research - October 26, 2009 Category: Biology Source Type: journals

"Agonizing" over Diabetes and Weight Gain{diamondsuit}: Peroxisome Proliferator-activated Receptor {gamma} Agonist Rosiglitazone Increases Expression of Very Low Density Lipoprotein Receptor Gene in Adipocytes [Papers Of The Week]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Biological Chemistry)
Source: Journal of Biological Chemistry - October 23, 2009 Category: Chemistry Tags: Papers Of The Week Source Type: journals

Peroxisome Proliferator-activated Receptor {gamma} Agonist Rosiglitazone Increases Expression of Very Low Density Lipoprotein Receptor Gene in Adipocytes [Metabolism and Bioenergetics]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Apolipoprotein E (apoE) and its receptor, very low density lipoprotein receptor (VLDLR), are involved in fat accumulation in adipocytes. Here, we investigated the effect of a peroxisome proliferator-activated receptor (PPAR) agonist, rosiglitazone, on regulation of VLDLR expression both in white adipose tissue (WAT) of obese mice and in cultured adipocytes. Furthermore, to determine whether rosiglitazone directly regulates transcription of the VLDLR gene, we carried out luciferase assay with a reporter gene containing mouse VLDLR promoter region, electrophoretic mobility shift assay, and chromatin immunoprecipitation assay...
Source: Journal of Biological Chemistry - October 23, 2009 Category: Chemistry Authors: Takazawa, T., Yamauchi, T., Tsuchida, A., Takata, M., Hada, Y., Iwabu, M., Okada-Iwabu, M., Ueki, K., Kadowaki, T. Tags: Metabolism and Bioenergetics Source Type: journals

Look at absolute event rates when interpreting trial resultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The low event rate in the RECORD trial of rosiglitazone has led some to question the validity of the results. (Source: theHeart.org)
Source: theHeart.org - October 23, 2009 Category: Cardiology Source Type: info

A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
HIV-infected patients on antiretroviral therapy frequently develop changes in body fat distribution and disturbances in glucose metabolism, associated with reduced adiponectin levels. Because adiponectin, principally the high-molecular-weight (HMW) form, has insulin-sensitizing properties, we investigated the effects of an increase in adiponectin on glucose metabolism in HIV-lipodystrophy. In this randomized, double-blind, placebo-controlled trial, we included HIV-1-infected patients with severe lipoatrophy, with an undetectable viral load and who had received neither protease inhibitors nor stavudine for ≥6 mo. Patient...
Source: AJP: Endocrinology and Metabolism - October 21, 2009 Category: Endocrinology Authors: Blumer, R. M. E., van der Valk, M., Ackermans, M., Endert, E., Serlie, M. J., Reiss, P., Sauerwein, H. P. Tags: Articles Source Type: journals

ACP Journal Club. Rosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetes.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PMID: 19841445 [PubMed - in process] (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - October 19, 2009 Category: Internal Medicine Authors: Lipscombe LL Tags: Ann Intern Med Source Type: journals

Commentary on 'case series of liver failure associated with rosiglitazone and pioglitazone' by James Floyd et alEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
No Abstract. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - October 18, 2009 Category: Drugs & Pharmacology Authors: Annette B. Beiderbeck, Motonobu Sakaguchi Source Type: journals

A randomised controlled trial on melatonin and rosiglitazone for prevention of adhesion formation in a rat uterine horn modelEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Rosiglitazone, but not melatonin, is effective in prevention of adhesion formation in a rat uterine horn model. Content Type Journal ArticleCategory General GynecologyDOI 10.1007/s00404-009-1240-8Authors Orhan Aksakal, Zekai Tahir Burak Women’s Health Education and Research Hospital Department of Obstetrics and Gynecology Ankara TurkeyBulent Yilmaz, Zekai Tahir Burak Women’s Health Education and Research Hospital Department of Obstetrics and Gynecology Ankara TurkeyTayfun Gungor, Zekai Tahir Burak Women’s Health Education and Research Hospital Department of Obstetrics and Gynecology Ank...
Source: Archives of Gynecology and Obstetrics - October 15, 2009 Category: OBGYN Tags: Archives of Gynecology and Obstetrics Source Type: journals

Induction of Uncoupling Protein-1 in Mouse Embryonic Fibroblast-derived Adipocytes by Retinoic Acid.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The uncoupling protein-1 (UCP1) is the molecular effector of thermogenesis in brown adipocytes, a process in which there is a renewed interest after the recent recognition of its relevance in adult humans. Typical white adipocytes do not express UCP1. We investigated the capacity of retinoic acid (RA), the carboxylic acid form of vitamin A and a known positive regulator of UCP1 gene transcription in brown adipocytes, to stimulate UCP1 expression in adipocytes differentiated in culture from primary mouse embryonic fibroblasts (MEFs), which are commonly used as white adipocyte model cells. Exposure to all-trans RA (ATRA)...
Source: Obesity - October 14, 2009 Category: Eating Disorders and Weight Management Authors: Mercader J, Palou A, Luisa Bonet M Tags: Obesity (Silver Spring) Source Type: journals

Complement Factor H is expressed in adipose tissue in association with insulin resistance.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Increased circulating fH and fB concentrations in subjects with altered glucose tolerance could reflect increased SVC-induced activation of the alternative pathway of complement in omental adipose tissue linked to insulin resistance and metabolic disturbances. PMID: 19833879 [PubMed - as supplied by publisher] (Source: Diabetes)
Source: Diabetes - October 14, 2009 Category: Endocrinology Authors: Moreno-Navarrete JM, Martínez-Barricarte R, Catalán V, Sabater M, Gómez-Ambrosi J, Ortega FJ, Ricart W, Blüher M, Frühbeck G, de Cordoba SR, Fernández-Real MJ Tags: Diabetes Source Type: journals

Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARγ and inhibition of ERK 1 / 2Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Alpha-eleostearic acid ([alpha]-ESA) is known to suppress the growth in cancer cells although its underlying molecular mechanisms have not been fully elucidated. The present study was designed to elucidate and evaluate the anticancer mechanism of [alpha]-ESA on MCF-7 breast cancer cells. Also, an attempt was made to better understand the anticancer mechanism by which [alpha]-ESA activated PPAR[gamma] and attenuated the ERK1/2 MAPK phosphorylation state. The MCF-7 breast cancer cell-line and nontumorigenic MCF-10A human mammary epithelial cells were treated with [alpha]-ESA and compared with negative control (without treatm...
Source: Cancer Science - October 10, 2009 Category: Cancer & Oncology Authors: Hyun-Seuk Moon, Ding-Ding Guo, Hong-Gu Lee, Yun-Jaie Choi, Jae-Seong Kang, Kyungmin Jo, Jung-Min Eom, Cheol-Heui Yun, Chong-Su Cho Source Type: journals

Tobacco smoke affects expression of peroxisome proliferator-activated receptor-γ in monocyte/macrophages of patients with coronary heart diseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions and implications: In CHD patients, exposure to tobacco smoke profoundly affected PPAR[gamma] expression, and this was related to levels of secretion of pro-inflammatory cytokines. MDMs from CHD smokers showed the lowest PPAR[gamma] expression and released more inflammatory cytokines. Moreover, rosiglitazone's ability to inhibit cytokine release and its reversal by GW9662 clearly indicated PPAR[gamma] involvement in these changes in CHD patients. (Source: British Journal of Pharmacology)
Source: British Journal of Pharmacology - October 7, 2009 Category: Drugs & Pharmacology Authors: A Amoruso, G Gunella, E Rondano, C Bardelli, LG Fresu, V Ferrero, F Ribichini, C Vassanelli, S Brunelleschi Source Type: journals

Thiazolidinediones once again linked to fracture riskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Risk appeared to be similar in men and women, with exposure to either rosiglitazone or pioglitazone, and across a range of fracture sites. The longer the duration of exposure to the drugs, the greater the risk. (Source: theHeart.org)
Source: theHeart.org - October 6, 2009 Category: Cardiology Source Type: info

Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin over Four-Years in Spite of Greater Weight Gain: Observations from ADOPT (A Diabetes Outcome Progression Trial).Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Rosiglitazone treatment was associated with durable reductions in CRP independent of changes in insulin sensitivity, HbA1c, and weight gain. CRP in the glyburide and metformin groups was positively associated with changes in weight, but this was not the case with rosiglitazone. PMID: 19808911 [PubMed - as supplied by publisher] (Source: Diabetes Care)
Source: Diabetes Care - October 5, 2009 Category: Endocrinology Authors: Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B, Tags: Diabetes Care Source Type: journals

Merck Blockbuster Diabetes Drug: Januvia Linked to PancreatitisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(NaturalNews) U.S. health officials said on Friday they suspect Merck`s blockbuster diabetes drug Januvia to be linked to pancreatitis, a potentially fatal condition marked by serious inflammation of the pancreas. As might be expected, Merck company officials disputed the connection.According to the Food and Drug Administration, 88 cases of acute pancreatitis had been reported since the drug`s approval in 2006 through February of this year by users of the drug and a related product Janumet, including two cases of hemorrhagic or necrotizing pancreatitis. The agency "believes there may be an association" with the drug, since...
Source: NaturalNews.com - October 5, 2009 Category: Consumer Health Advice Source Type: news

Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Type 2 diabetes is associated with substantially increased cardiovascular mortality. The need to reduce the progression of atherosclerosis alongside lowering blood glucose levels is now well established. Ideally, pharmaceutical treatment should address both of these needs. This review summarises current evidence of the anti-atherosclerotic effects exerted by oral antidiabetic agents. Metformin has so far consistently succeeded in reducing cardiovascular morbidity and mortality and exerting beneficial effects on lipids. Of the new agents, thiazolidinediones (rosiglitazone and pioglitazone) have been most widely studied....
Source: Current Pharmaceutical Design - October 1, 2009 Category: Drugs & Pharmacology Authors: Papanas N, Maltezos E Tags: Curr Pharm Des Source Type: journals

Rosiglitazone Tied to Fracture Risk in MenEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Rosiglitazone use was associated with an increased prevalence of vertebral fractures among men in a small cross-sectional study. Most previous studies on the effect of thiazolidinediones on bone have been done in postmenopausal women, who are already at risk for osteoporosis. The present study provides evidence that osteoporotic fractures may be a general complication of this treatment, said Dr. Tatiana Mancini of San Marino (Italy) Hospital, and her associates. (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - September 30, 2009 Category: Endocrinology Authors: CAROLINE HELWICK Tags: Osteoporosis Source Type: news

More evidence that glitazones increase fracture riskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study design is useful for identifying the effects of short-term exposures to some intervention: each case acts as their own control, reducing the number of confounding factors that have to be controlled for. From the UK General Practice Research Database (GPRD), the authors identified all patients aged over 40 who were recorded as having had a fracture and who had at least one prescription for a glitazone. They then calculated ... (Source: NeLM - News)
Source: NeLM - News - September 29, 2009 Category: Drugs & Pharmacology Source Type: organizations

When is evidence of lack of harm enough? Has the rosiglitazone controversy ended?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Content Type Journal ArticleCategory Clinical Trials ReportDOI 10.1007/s11892-009-0063-0Authors Anthony L. McCall, University of Virginia Health System Diabetes and Hormone Center of Excellence Box 801407 450 Ray C. Hunt Drive Charlottesville VA 22908 USA Journal Current Diabetes ReportsOnline ISSN 1539-0829Print ISSN 1534-4827 Journal Volume Volume 9 Journal Issue Volume 9, Number 5 / October, 2009 (Source: Current Diabetes Reports)
Source: Current Diabetes Reports - September 29, 2009 Category: Endocrinology Tags: Current Diabetes Reports Source Type: journals

Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and downregulation of NKCC2 protein expressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sirolimus, an antiproliferative immunosuppressant, induces hypomagnesemia and hypokalemia. Rosiglitazone activates renal sodium- and water-reabsorptive pathways. We evaluated whether sirolimus induces renal wasting of magnesium and potassium, attempting to identify the tubule segments in which this occurs. We tested the hypothesis that reduced expression of the cotransporter NKCC2 forms the molecular basis of this effect and evaluated the possible association between increased urinary excretion of magnesium and renal expression of the epithelial Mg2+ channel TRPM6. We then analyzed whether rosiglitazone attenuates these si...
Source: AJP: Renal Physiology - September 27, 2009 Category: Urology & Nephrology Authors: Alexandre, C. d. S., de Braganca, A. C., Shimizu, M. H. M., Sanches, T. R., Fortes, M. A. Z., Giorgi, R. R., Andrade, L., Seguro, A. C. Tags: ARTICLES Source Type: journals

Molecular mechanisms underlying the pro-inflammatory synergistic effect of tumor necrosis factor alpha and interferon gamma in human microvascular endothelium.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Tumor necrosis factor alpha (TNFalpha) and interferon gamma (IFNgamma) are among the most potent cytokines involved in orchestrating the inflammation response. The molecular mechanisms implicated in the synergism between cytokines are still poorly characterized. We demonstrate that both cytokines dose-dependently stimulate IFNgamma-inducible-protein-of-10-kDa (IP-10) secretion in human microvascular endothelial cells (HMEC-1), showing a potent synergism which is not restricted to IP-10, but is also evident for monokine-induced-by-IFNgamma (MIG) and IL-6 secretion. Immunofluorescence analysis reveals that TNFalpha and I...
Source: European Journal of Cell Biology - September 24, 2009 Category: Cytology Authors: Lombardi A, Cantini G, Mello T, Francalanci M, Gelmini S, Cosmi L, Santarlasci V, Degl'innocenti S, Luciani P, Deledda C, Annunziato F, Forti G, Galli A, Serio M, Luconi M Tags: Eur J Cell Biol Source Type: journals

Rosiglitazone, peroxisome proliferator receptor-gamma agonist, ameliorates gentamicin-induced nephrotoxicity in ratsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study was performed to investigate the protective role of PPAR-γ agonist against GEN-induced nephrotoxicity. Male Wistar Albino rats were randomly divided into the following four groups, each of which consisted of six animals: (1) control; (2) intraperitoneally injected with GEN for 14 consecutive days (100 mg/kg/day); (3) treatment with rosiglitazone (RSG) via nasogastric gavage (10 mg/kg/daily for 14 days); (4) treatment with GEN + RSG combination for 14 day. Rats were decapitated on the 15th day and kidneys were removed. Urine was collected for every 24 h for the determination of...
Source: International Urology and Nephrology - September 24, 2009 Category: Urology & Nephrology Tags: International Urology and Nephrology Source Type: journals

PPAR-{gamma} agonist rosiglitazone reverses increased cerebral venous hydraulic conductivity during hypertensionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Peroxisome proliferator-activated receptor- (PPAR-) agonists have been shown to protect the cerebral vasculature, including the blood-brain barrier. In the present study, we investigated the effect of the PPAR- agonist rosiglitazone on changes in venous permeability during chronic hypertension induced by nitric oxide synthase inhibition. Female Sprague-Dawley rats were either treated with NG-nitro-l-arginine methyl ester (l-NAME; 0.5 g/l in drinking water) for 5 wk (HTN; n = 8), l-NAME for 5 wk plus the PPAR- agonist rosiglitazone (20 mg/kg in food) for the last 3 wk (HTN + Rosi; n = 5), l-NAME for 5 wk plus the superoxide...
Source: AJP: Heart and Circulatory Physiology - September 23, 2009 Category: Cardiology Authors: Roberts, T. J. M., Chapman, A. C., Cipolla, M. J. Tags: ARTICLES Source Type: journals

Differential Healing After Sirolimus, Paclitaxel, and Bare Metal Stent Placement in Combination With Peroxisome Proliferator-Activator Receptor {gamma} Agonists. Requirement for mTOR/Akt2 in PPAR{gamma} Activation.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: mTOR/Akt2 is required for optimal PPARgamma activation. Patients who receive SESs during concomitant RSG treatment may be at risk for delayed stent healing. PMID: 19797172 [PubMed - as supplied by publisher] (Source: Circulation Research)
Source: Circulation Research - September 23, 2009 Category: Cardiology Authors: Finn AV, John M, Nakazawa G, Polavarapu R, Karmali V, Xu X, Cheng Q, Davis T, Raghunathan C, Acampado E, Ezell T, Lajoie S, Eppihimer M, Kolodgie FD, Virmani R, Gold HK Tags: Circ Res Source Type: journals

Rosiglitazone Effects to Ameliorate Alzheimer's Disease Pathogenic Features: Insulin Signaling and Neurotrophic Factors [LETTERS TO THE EDITOR]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: J Neuropsychiatry Clin Neurosci)
Source: J Neuropsychiatry Clin Neurosci - September 22, 2009 Category: Neurology Authors: Castillo-Quan, J. I. Tags: LETTERS TO THE EDITOR Source Type: journals

Diabetes Drug Shows Promise in Fighting Lethal Cancer ComplicationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, mice were fed a high-fat diet and randomized into three groups: mice with and without tumors receiving a saline solution as a control, and mice with tumors treated with daily injections of rosiglitazone. Within eight days, the mice with cancer receiving the rosiglitazone showed more sensitivity to insulin than did the mice with tumors that received no medication. The insulin sensitivity of the medicated mice matched that of mice without tumors. Similarly, the mice receiving rosiglitazone actually gained weight in this study, as did the mice without tumors. The mice with tumors receiving no treatment lost f...
Source: Diabetes News from dLife.com - September 22, 2009 Category: Consumer Health News Authors: dlife Source Type: info

Berberine improves free-fatty-acid–induced insulin resistance in L6 myotubes through inhibiting peroxisome proliferator–activated receptor γ and fatty acid transferase expressionsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: The plant alkaloid berberine (BBR) has been reported to have antidiabetic effect in humans and animals. However, the mechanism of action is not well understood. The present study was conducted to determine the effect and mechanism of action of BBR on the free-fatty-acid (FFA)–induced insulin resistance in muscle cells. The FFA-induced insulin-resistant cell model was established in L6 myotubes by treating them with 250 μmol/L of palmitic acid. The inclusion of FFA in the medium increased peroxisome proliferator–activated receptor γ (PPARγ) and fatty acid transferase (FAT/CD36) expressions by 26% and 50% an...
Source: Metabolism - Clinical and Experimental - September 22, 2009 Category: Biomedical Science Authors: Yanfeng Chen, Ying Li, Yanwen Wang, Ying Wen, Changhao Sun Source Type: journals